Labiotech.eu

Bayer has a lot on its plate; lawsuits, patent cliffs, drug development, and potential FDA approvals. Is it ready to make a comeback in 2026? The post Blockbuster sales, lawsuits, and approvals: is there a recovery in sight for Bayer in 2026? appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permissio…

This week, the 2026 LSX Nordic Congress was held in Copenhagen. Find out what came out of the Nordic-focused partnering event. The post LSX Nordic Congress 2026: what came out of the biotech partnering event appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or ow…

Our two guests this week: Quin Wills, CEO of Ochre Bio, and Stéphane Barges, CEO of Lexogen. The post The problem at the heart of drug discovery: Lexogen & Ochre Bio on the power of AI on human data appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is st…

For nearly thirty years, there have been no FDA-approved drugs for pattern hair loss, but this could change soon as therapies near approval. The post Treating pattern hair loss: how close are we? appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is stric…

As Sweden's life sciences sector continues to grow, we explore 8 biotech companies in Sweden that are leading the way in the industry. The post Eight Swedish companies spearheading the country’s biotech scene appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or o…

Delve into the field of RAS inhibitors, an area of biotechnology that is increasingly diversifying to tackle pancreatic cancer, among other cancers. The post RAS inhibition enters its second wave appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is stric…

Contamination in suspension cell culture can affect results. Learn how CO₂ incubator shaker design reduces contamination risk. The post Reducing cell culture contamination: Why sterilisation validation matters in CO₂ shaking workflows appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from t…

Take a look at how new antidepressants can more effectively tackle treatment resistant depression compared to more traditional treatments. The post New antidepressants: Tackling treatment resistant depression appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or o…

No medicines have been approved for stiff person syndrome yet. However, Kyverna Therapeutics' CAR-T cell therapy is headed towards approval. The post CAR-T therapy for stiff person syndrome nears approval appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner…

Our guest today is Dominic Clark, Vice President of Technical Operations for IntegriCell at Cryoport Systems. The post Freeze variability, not progress: strengthen your cell therapy supply chain from the start appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or …

Find out what investors now look for in an AI biotech company, now that the hype has settled and AI enters a more pragmatic era. The post What investors now expect from AI biotech companies appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly pr…

The first TIL therapy received FDA approval two years ago. What does the field look like now? The post TIL therapies: the impact on cancer research appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, …

Discover the potential long-term risks caused by biotech layoffs and how biotech risk management is vital in this situation. The post Biotech risk management: The hidden risks behind layoffs appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly p…

Learn how cryopreservation improves scalability and helps CGT programs move from early development to commercial manufacturing. The post The real reason CGT programs struggle to scale appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibit…

Delve into the Australian biotech giant CSL's strategy to refocus a company built on complex modalities. The post Inside CSL’s strategy to simplify a biotech giant appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and lin…

Kailera Therapeutics, Nektar Therapeutics, and Hemab Therapeutics bagged the biggest biotech funding rounds overall in April 2026. The post The biggest biotech funding rounds in April 2026 appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly pro…

Discover the field of trispecific antibodies, which are currently generating strong interest across the biopharma industry. The post The rise of trispecific antibodies: Biopharma’s next big bet after bispecifics appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/o…

Today, we dive into the future of lab management with Ryan Cawood, CEO and co-founder of Lab Thread. The post Making labs smarter for scientific breakthroughs appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links ma…

The biggest biotech acquisition deal so far in 2026 was announced in April. Deals were sealed over ADCs, small molecules, AI platforms, and T-cell engagers. The post Top biotech deals in April 2026 appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is str…

Look into what biotech companies are developing for sickle cell disease after Casgevy's approval in 2023. The post Sickle cell disease after Casgevy: seven companies to watch in 2026 appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibite…